PMID- 30134234
OWN - NLM
STAT- MEDLINE
DCOM- 20181224
LR  - 20181224
IS  - 1421-9875 (Electronic)
IS  - 0257-2753 (Linking)
VI  - 37
IP  - 1
DP  - 2019
TI  - Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's 
      Disease at a Tertiary Referral Center.
PG  - 33-44
LID - 10.1159/000492322 [doi]
AB  - BACKGROUND: Vedolizumab was approved for the therapy of ulcerative colitis and 
      Crohn's disease in mid-2014. Real-world treatment data are necessary for a 
      balanced assessment of its position among other therapeutic options. SUMMARY: 
      Patients with ulcerative colitis or Crohn's disease, initiating vedolizumab 
      therapy at the outpatient clinic for inflammatory bowel diseases at the 
      University Hospital -Heidelberg between June 1, 2014 and August 31, 2016, were 
      recruited based on electronic medical records. The primary study endpoint was 
      response at week 30, while the secondary endpoints were the need for surgery and 
      discontinuation of therapy due to inadequate response, or adverse events. 
      Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor alpha 
      [TNFalpha] naive) and 28 patients with Crohn's disease (10.7% anti-TNFalpha naive, 53.6% 
      having undergone at least one intestinal surgery) were enrolled. Among the 
      ulcerative colitis patients, 20% achieved remission, 32% partial response, and 
      48% were non-responders to vedolizumab. In Crohn's disease, 14.3% of the patients 
      achieved remission, 46.4% partial response, and 39.4% were non-responders. Two 
      patients discontinued vedolizumab therapy due to suspected side effects. Key 
      Message: In a relatively treatment-refractory cohort of inflammatory bowel 
      disease patients, vedolizumab was efficacious in achieving response. However, the 
      majority of the patients were not satisfactorily treated, as they did not reach 
      remission.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Hoffmann, Peter
AU  - Hoffmann P
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germanypeter.hoffmann@med.uni-heidelberg.de.
FAU - Krisam, Johannes
AU  - Krisam J
AD  - Department of Medical Biometry, University Hospital Heidelberg, Institute of 
      Medical Biometry and Informatics, Heidelberg, Germany.
FAU - Stremmel, Wolfgang
AU  - Stremmel W
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Gauss, Annika
AU  - Gauss A
AD  - Department of Gastroenterology and Hepatology, University Hospital Heidelberg, 
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180822
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 9RV78Q2002 (vedolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Cohort Studies
MH  - Colitis, Ulcerative/*drug therapy
MH  - Crohn Disease/*drug therapy
MH  - Endpoint Determination
MH  - Female
MH  - Humans
MH  - Male
MH  - *Referral and Consultation
MH  - *Tertiary Care Centers
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Crohn's disease
OT  - Inflammatory bowel disease
OT  - Real-world
OT  - Ulcerative colitis
OT  - Vedolizumab
EDAT- 2018/08/23 06:00
MHDA- 2018/12/26 06:00
CRDT- 2018/08/23 06:00
PHST- 2018/03/07 00:00 [received]
PHST- 2018/07/23 00:00 [accepted]
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2018/12/26 06:00 [medline]
PHST- 2018/08/23 06:00 [entrez]
AID - 000492322 [pii]
AID - 10.1159/000492322 [doi]
PST - ppublish
SO  - Dig Dis. 2019;37(1):33-44. doi: 10.1159/000492322. Epub 2018 Aug 22.